Storia in 6 fonti

FDA Approves First CELMoD Drug for Multiple Myeloma

Iberdomide indicated as part of combination regimen for relapsed or refractory disease

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo2 g fa

FDA Approves First CELMoD Drug for Multiple Myeloma

Iberdomide indicated as part of combination regimen for relapsed or refractory disease

originale

healio.com

Timeline cronologica

giovedì 13 agosto 2026·medpagetoday.com
FDA Approves First CELMoD Drug for Multiple Myeloma
Iberdomide indicated as part of combination regimen for relapsed or refractory disease
giovedì 13 agosto 2026·morningstar.com
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and…
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for…

2 g fa

Zenbexus-led combination nabs FDA’s first CELMoD therapy approval in multiple myeloma

The FDA has granted accelerated approval to the first cereblon E3 ligase modulation therapy for patients with multiple myeloma.Iberdomide (Zenbexus, Bristol Myers Squibb), in combination with daratumumab and…

Leggi questa versione → originale

benzinga.com1 g fa

Bristol Myers Squibb Gets FDA Nod For Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)

Bristol Myers Squibb secures FDA approval for Zenbexus (iberdomide), marking the first CELMoD therapy approval.

Leggi questa versione → originale

morningstar.com2 g fa

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination…

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early…

Leggi questa versione → originale

endpoints.news2 g fa

FDA approves Bristol Myers’ multiple myeloma successor

FDA approved Bristol Myers Squibb's iberdomide (Zenbexus) for relapsed/refractory multiple myeloma at $29,500/cycle, used with Darzalex and dexamethasone.

Leggi questa versione → originale

biopharmadive.com2 g fa

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

Leggi questa versione → originale

giovedì 13 agosto 2026·

endpoints.news

FDA approves Bristol Myers’ multiple myeloma successor

FDA approved Bristol Myers Squibb's iberdomide (Zenbexus) for relapsed/refractory multiple myeloma at $29,500/cycle, used with Darzalex and dexamethasone.

venerdì 14 agosto 2026·

healio.com

Zenbexus-led combination nabs FDA’s first CELMoD therapy approval in multiple myeloma

The FDA has granted accelerated approval to the first cereblon E3 ligase modulation therapy for patients with multiple myeloma.Iberdomide (Zenbexus, Bristol Myers Squibb), in…

venerdì 14 agosto 2026·

biopharmadive.com

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

The clearance of Zenbexus is the first for a group of protein-degrading “CELMoD” medicines that could help Bristol Myers rejuvenate a key drug franchise.

venerdì 14 agosto 2026·

benzinga.com

Bristol Myers Squibb Gets FDA Nod For Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)

Bristol Myers Squibb secures FDA approval for Zenbexus (iberdomide), marking the first CELMoD therapy approval.

FDA Approves First CELMoD Drug for Multiple Myeloma

Timeline cronologica

FDA Approves First CELMoD Drug for Multiple Myeloma

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and…

Zenbexus-led combination nabs FDA’s first CELMoD therapy approval in multiple myeloma

Bristol Myers Squibb Gets FDA Nod For Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination…

FDA approves Bristol Myers’ multiple myeloma successor

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

FDA approves Bristol Myers’ multiple myeloma successor

Zenbexus-led combination nabs FDA’s first CELMoD therapy approval in multiple myeloma

Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene

Bristol Myers Squibb Gets FDA Nod For Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)